The Genetic Basis for Cancer Treatment Decisions

[1]  AC Tose.  Cell , 1993, Cell.

[2]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[3]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[4]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[5]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Flanagan,et al.  In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours , 2004, The Journal of pathology.

[7]  J. Benkendorf,et al.  The state of the medical geneticist workforce: Findings of the 2003 survey of American Board of Medical Genetics certified geneticists , 2005, Genetics in Medicine.

[8]  Stephen Little,et al.  The impact of FDA guidance on pharmacogenomic data submissions on drug development. , 2005, IDrugs : the investigational drugs journal.

[9]  J. Benkendorf,et al.  The medical genetics workforce: An analysis of clinical geneticist subgroups , 2006, Genetics in Medicine.

[10]  G. Pond,et al.  Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[12]  P. Spellman,et al.  High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays , 2009, BMC Medical Genomics.

[13]  J. Trent,et al.  Using biointelligence to search the cancer genome: an epistemological perspective on knowledge recovery strategies to enable precision medical genomics , 2008, Oncogene.

[14]  I. Floriani,et al.  High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. , 2008, The oncologist.

[15]  E. Stathopoulos,et al.  Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC , 2008, British Journal of Cancer.

[16]  A. McGuire,et al.  Research ethics and the challenge of whole-genome sequencing , 2008, Nature Reviews Genetics.

[17]  Keith L. Ligon,et al.  Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples , 2009, PloS one.

[18]  S. Paik,et al.  A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes , 2010, BMC Cancer.

[19]  klaguia.  Prepublication Data Sharing , 2009 .

[20]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[21]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[22]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[23]  J. Berek,et al.  Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. , 2010, Gynecologic oncology.

[24]  A. Sparks,et al.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient , 2010, Nature.

[25]  J. Barrett,et al.  PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer , 2010, Clinical Cancer Research.

[26]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[27]  S. Turner,et al.  Real-time DNA sequencing from single polymerase molecules. , 2010, Methods in enzymology.

[28]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[29]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[30]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[31]  Steven J. M. Jones,et al.  Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors , 2010, Genome Biology.

[32]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[33]  Michael Bittner,et al.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  David N Louis,et al.  Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine , 2010, EMBO molecular medicine.

[35]  Iwanka Kozarewa,et al.  96-plex molecular barcoding for the Illumina Genome Analyzer. , 2011, Methods in molecular biology.

[36]  B. Chabner.  Early accelerated approval for highly targeted cancer drugs. , 2011, The New England journal of medicine.

[37]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[38]  T. Hudson,et al.  Unraveling the genetics of cancer: genome sequencing and beyond. , 2011, Annual review of genomics and human genetics.

[39]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[40]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[41]  I. Nagtegaal,et al.  KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients , 2011, British Journal of Cancer.

[42]  M. Stratton.  Exploring the Genomes of Cancer Cells: Progress and Promise , 2011, Science.

[43]  F. Staff.  FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer , 2011 .

[44]  J. Reis-Filho,et al.  Next-generation sequencing applied to molecular diagnostics , 2011, Expert review of molecular diagnostics.

[45]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[46]  Bernard P. Puc,et al.  An integrated semiconductor device enabling non-optical genome sequencing , 2011, Nature.

[47]  Doris Berger,et al.  International Cancer Genome Consortium , 2013, Im Focus Onkologie.